BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24080892)

  • 1. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].
    Picazo JJ; González-Romo F; García Rojas A; Peréz-Trallero E; Gil Gregorio P; de la Cámara R; Morató ML; Rodríguez A; Barberán J; Domínguez Hernández V; Linares Rufo M; Jimeno Sanz I; Portolés JM; Sanz Herrero F; Espinosa Arranz J; García-Sánchez V; Galindo Izquierdo M
    Rev Esp Quimioter; 2013 Sep; 26(3):232-52. PubMed ID: 24080892
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vaccination against pneumococcal infection in adults].
    Viejo JL
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():26-8. PubMed ID: 20084346
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunization and antimicrobials. Is there an association between the effects against Streptococcus pneumoniae?].
    Aguilar L; Giménez MJ
    Rev Esp Quimioter; 2007 Mar; 20(1):125-7. PubMed ID: 17530045
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pneumococcal infections: Appraisal and perspectives in terms of adult vaccination].
    Baratali L; Lang PO
    Presse Med; 2015 Nov; 44(11):1155-61. PubMed ID: 26363530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines: worth paying for the value returned.
    Grabenstein JD
    Ann Pharmacother; 2002 Sep; 36(9):1471-2. PubMed ID: 12229878
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance].
    Traut V
    Dtsch Med Wochenschr; 2008 May; 133(22):1207-8; author reply 1208. PubMed ID: 18491279
    [No Abstract]   [Full Text] [Related]  

  • 11. Pneumococcal vaccination of adults: polysaccharide or conjugate.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47-8. PubMed ID: 19528887
    [No Abstract]   [Full Text] [Related]  

  • 12. Pneumococcal infection in adults: burden of disease.
    Drijkoningen JJ; Rohde GG
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():45-51. PubMed ID: 24313448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccines in adults: assessing the evolving evidence.
    Grabenstein JD; Manoff SB
    Vaccine; 2011 Aug; 29(37):6149-54. PubMed ID: 21763386
    [No Abstract]   [Full Text] [Related]  

  • 17. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation.
    Ispahani P; Slack RC; Donald FE; Weston VC; Rutter N
    Arch Dis Child; 2004 Aug; 89(8):757-62. PubMed ID: 15269078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promises and challenges of pneumococcal conjugate vaccines for the developing world.
    Grijalva CG; Edwards KM
    Clin Infect Dis; 2006 Sep; 43(6):680-2. PubMed ID: 16912938
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotype replacement in perspective.
    Dagan R
    Vaccine; 2009 Aug; 27 Suppl 3():C22-4. PubMed ID: 19545935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.
    Grau I; Ardanuy C; Liñares J; Podzamczer D; Schulze MH; Pallares R
    HIV Med; 2009 Sep; 10(8):488-95. PubMed ID: 19459987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.